IN2015DN01147A - - Google Patents

Info

Publication number
IN2015DN01147A
IN2015DN01147A IN1147DEN2015A IN2015DN01147A IN 2015DN01147 A IN2015DN01147 A IN 2015DN01147A IN 1147DEN2015 A IN1147DEN2015 A IN 1147DEN2015A IN 2015DN01147 A IN2015DN01147 A IN 2015DN01147A
Authority
IN
India
Prior art keywords
composition
variable domain
single variable
treatment
stabilising
Prior art date
Application number
Inventor
Sean Matthew Cleveland
Stefan Salomon
Cassandra Van Krinks
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IN2015DN01147A publication Critical patent/IN2015DN01147A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present disclosure provides a means of stabilising a single variable domain in particular in protease rich environments such as the stomach and intestine. A composition in particular a pharmaceutical composition comprising a single variable domain and camostat mesylate is provided together with uses of said composition as a medicament and in methods of treatment. Compositions of the disclosure are particularly useful in the topical treatment of gastrointestinal conditions such as Crohn's Disease or ulcerative colitis or for direct activity in the gut mucosal immune system.
IN1147DEN2015 2012-08-21 2015-02-12 IN2015DN01147A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261691443P 2012-08-21 2012-08-21
PCT/IB2013/001814 WO2014030049A2 (en) 2012-08-21 2013-08-21 Compositions comprising a single variable domain and camostat mesylate (cm)

Publications (1)

Publication Number Publication Date
IN2015DN01147A true IN2015DN01147A (en) 2015-06-26

Family

ID=49510445

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1147DEN2015 IN2015DN01147A (en) 2012-08-21 2015-02-12

Country Status (11)

Country Link
US (1) US20150306058A1 (en)
EP (1) EP2887960A2 (en)
JP (1) JP2015527357A (en)
KR (1) KR20150043342A (en)
CN (1) CN104884089A (en)
AU (1) AU2013304627A1 (en)
BR (1) BR112015003851A2 (en)
CA (1) CA2882684A1 (en)
IN (1) IN2015DN01147A (en)
RU (1) RU2015110027A (en)
WO (1) WO2014030049A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
CN113016720B (en) * 2014-11-24 2023-02-21 瑞泽恩制药公司 Non-human animals expressing humanized CD3 complexes
CN114920847A (en) * 2015-05-13 2022-08-19 埃博灵克斯股份有限公司 T cell recruitment polypeptides based on CD3 responsiveness
KR102194188B1 (en) 2015-11-18 2020-12-24 머크 샤프 앤드 돔 코포레이션 PD1 and/or LAG3 binder
JP7000322B2 (en) 2015-12-16 2022-02-04 メルク・シャープ・アンド・ドーム・コーポレーション Anti-LAG3 antibody and antigen-binding fragment
SG11201807402PA (en) * 2016-03-31 2018-09-27 Vhsquared Ltd Compositions
MX2021015761A (en) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polypeptides.
CN114514243A (en) 2019-06-21 2022-05-17 索瑞索制药公司 Polypeptides
WO2021188815A1 (en) * 2020-03-18 2021-09-23 Memorial Sloan Kettering Cancer Center Inhalational therapy for covid-19

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions

Also Published As

Publication number Publication date
RU2015110027A (en) 2016-10-10
KR20150043342A (en) 2015-04-22
EP2887960A2 (en) 2015-07-01
CN104884089A (en) 2015-09-02
WO2014030049A3 (en) 2014-04-17
US20150306058A1 (en) 2015-10-29
AU2013304627A1 (en) 2015-02-26
BR112015003851A2 (en) 2017-08-08
WO2014030049A2 (en) 2014-02-27
CA2882684A1 (en) 2014-02-27
JP2015527357A (en) 2015-09-17

Similar Documents

Publication Publication Date Title
IN2015DN01147A (en)
BR112014032699A2 (en) Pediatric metabolic syndrome treatment methods
PL2753343T3 (en) Composition comprising n-acetylcysteine and probiotic bacteria capable of restoring the stomach's own barrier effect which is lost during treatment of gastric hyperacidity with proton pump inhibitors
MX2020010535A (en) Methods of treating cancer.
BR112013026690A2 (en) A composition comprising probiotic bacteria capable of restoring the stomach barrier effect that is lost during the pharmacological treatment of gastric hyperacidity.
IN2012DN06720A (en)
EP2528934A4 (en) Aromatic-cationic peptides and uses of same
SI2935303T1 (en) 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv
MX2021000715A (en) Compositions and methods for treating metabolic disorders.
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
MX2013004061A (en) Cyclosporin analogs.
MX2016003490A (en) Co rti statin analogues for the treatment of inflammatory and/or immune diseases.
SG10201502583VA (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
MX364220B (en) Methods of treating fibrosis.
MY168778A (en) Oligonucleotide chelate complex-polypeptide compositions and methods
MX2015000485A (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine.
IN2014DN07326A (en)
IL251687B (en) Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patients which have been subjected to gastric bypass-surgery
WO2014030052A3 (en) Compositions comprising an antibody and camostat mesylate (cm)
MA41220A (en) DIETARY SUPPLEMENT CONSISTING OF A BLEND OF MAGNESIUM OXIDE AND MAGNESIUM CARBONATE
EA201590732A1 (en) DISPENSABLE TABLET
BR112014015193A2 (en) glycoprotein enriched composition as a food and / or feed additive and / or as a therapeutic agent
AU2016903444A0 (en) This invention is a lightweight, closely-fitted yet non-restrictive shirt containing three long pockets; two of which run along the full length of both sides of the shirt and one that runs down the full length of the back of the shirt along the length of the spine. Into these pockets, specially shaped long pads of varying dimensions can be inserted which act as spinal support and as non-invasive correctional treatment to be used in conjunction with such non-invasive treatment methods when the shirt is worn.
MX2017011838A (en) Compositions and methods for treating hepatocellular carcinoma.
TR201204288A2 (en) Tablet formulation containing levodopa, carbidopa, entacapone.